A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT ID: NCT05296798
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
922 participants
INTERVENTIONAL
2022-07-18
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02132949
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
NCT00567190
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
NCT05638594
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Induction Therapy: Phesgo plus Taxane-Based Chemotherapy
Phesgo
Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
Docetaxel
During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
Paclitaxel
During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
Arm A, Maintenance Therapy: Phesgo
Phesgo
Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
LHRH Agonist
A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Optional Endocrine Therapy of Investigator's Choice
For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
Arm B, Maintenance Therapy: Giredestrant plus Phesgo
Phesgo
Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
Giredestrant
A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
LHRH Agonist
A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phesgo
Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
Giredestrant
A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
Docetaxel
During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
Paclitaxel
During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
LHRH Agonist
A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Optional Endocrine Therapy of Investigator's Choice
For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of ≥6 months
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
* Left ventricular ejection fraction (LVEF) of at least (≥)50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
* Adequate hematologic and end-organ function
* For women of childbearing potential: Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 7 months after the final dose of Phesgo
* For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo
* Complete a minimum of four cycles to a maximum of eight cycles of induction therapy; the minimum cycles are defined as either: Phesgo injections + 4 docetaxel infusions, or Phesgo injections + 12 paclitaxel infusions
* Achieve a minimum of stable disease (SD) (or Non-complete response \[CR\]/Non-progressive disease \[PD\] for participants with non-measurable disease) (i.e., did not experience PD) according to RECIST v1.1 at the last tumor assessment during the induction therapy phase
* LVEF of ≥50% at the last assessment during the induction therapy phase
Exclusion Criteria
* Prior treatment with a selective estrogen receptor degrader (SERD)
* Previous treatment with approved or investigative anti-HER2 agents in any breast cancer treatment setting, except Phesgo (or trastuzumab SC with pertuzumab IV, or pertuzumab and trastuzumab IV), single-agent trastuzumab IV or SC, ado-trastuzumab emtansine, lapatinib, and neratinib in the neoadjuvant or adjuvant setting
* Disease progression within 6 months of receiving adjuvant anti-HER2 therapy (such as trastuzumab, with or without pertuzumab \[IV, SC, or fixed-dose combination\], or ado-trastuzumab emtansine, or neratinib)
* Non-resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) Grade 1 or better
* History of persistent Grade ≥2 (NCI-CTC, Version 5.0) hematological toxicity resulting from previous adjuvant or neo-adjuvant therapy
* History of exposure to the following cumulative doses of anthracyclines; Doxorubicin \>360 mg/m2; Liposomal doxorubicin \>500 mg/m2; Epirubucin \>720 mg/m2; Mitoxantrone \>120 mg/m2; Idarubicin \>90 mg/m2.
* Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease
* Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
* Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the final dose of Phesgo (Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of induction therapy).
* Treated with investigational therapy within 28 days prior to initiation of induction therapy
* Treated with localized palliative radiotherapy within 14 days prior to initiation of induction therapy
* Concurrent participation in any other therapeutic clinical trial
* Known hypersensitivity to any of the study medications or to excipients of recombinant human or humanized antibodies
* Current chronic daily treatment (continuous for \>3 months) with corticosteroids (dose of 10 mg/day methylprednisolone or equivalent)
* Poorly controlled hypertension
* Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, active liver disease including active viral or other hepatitis virus, autoimmune hepatic disorders, or sclerosing cholangitis, current alcohol abuse, or cirrhosis
* Active cardiac disease or history of cardiac dysfunction
* Major surgical procedure or significant traumatic injury within 14 days prior to enrollment or anticipation of need for major surgery during induction therapy
* Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery
* Concurrent, serious, uncontrolled infections, or known infection with HIV with the following exception: Individuals who are HIV positive are eligible provided they are stable on anti-retroviral therapy for ≥4 weeks, have a CD4 count ≥350 cells/uL, and have an undetectable viral load and no history of AIDS-defining opportunistic infections within 12 months prior to enrollment.
* Serious COVID-19 infection within 14 days prior to enrollment; however, no screening testing for SARS-CoV-2 is required
* Serious infection requiring oral or IV antibiotics within 7 days prior to screening
* Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in the study
* History of malignancy within 5 years prior to screening with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death
* For pre- and perimenopausal women, and men: Known hypersensitivity to luteinizing hormone-releasing hormone agonist (LHRHa); Not willing to undergo and maintain treatment with approved LHRHa therapy for the duration of endocrine therapy that requires gonadal function suppression
* Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of giredestrant treatment in Arm B
* A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism, including deep vein thrombosis, unless the condition is adequately treated and under control
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Clinical Research Center, Inc
Tucson, Arizona, United States
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Carle Cancer Center
Urbana, Illinois, United States
Maryland Oncology Hematology - Annapolis
Annapolis, Maryland, United States
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
St. Joseph Mercy Oakland
Pontiac, Michigan, United States
Queens Hospital Cancer Center
Jamaica, New York, United States
Clinical Research Alliance
Westbury, New York, United States
West Cancer Center
Germantown, Tennessee, United States
CHRISTUS Spohn Cancer Center - Shoreline
Corpus Christi, Texas, United States
Texas Oncology - DFW
Dallas, Texas, United States
Texas Oncology - El Paso
El Paso, Texas, United States
CHRISTUS St. Michael Health System
Texarkana, Texas, United States
Swedish Cancer Institute - Edmonds Campus
Edmonds, Washington, United States
Swedish Cancer Institute - Issaquah
Issaquah, Washington, United States
Swedish Cancer Institute
Seattle, Washington, United States
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, , Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, , Argentina
Fundacion Centro Oncologico de Integracion Regional (COIR)
Mendoza, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Hospital Provincial del Centenario
Rosario, , Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, , Argentina
GHdC Site Les Viviers
Charleroi, , Belgium
UZ Gent
Ghent, , Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Clinique Ste-Elisabeth
Namur, , Belgium
Pronutrir - suporte nutricional e quimioterapia ltda.
Fortaleza, Ceará, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Hospital do Câncer de Londrina
Londrina, Paraná, Brazil
Hospital do Cancer de Pernambuco - HCP
Recife, Pernambuco, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Amor Amazônia
Porto Velho, Rondônia, Brazil
Fundação Pio XII Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, Brazil
Affiliated Hospital of Hebei University
Baoding, , China
Peking University People's Hospital
Beijing, , China
the First Affiliated Hospital of Bengbu Medical College
Bengbu, , China
The First Hospital of Jilin University
Changchun, , China
Hunan Cancer Hospital
Changsha, , China
Sichuan Cancer Hospital
Chengdu, , China
West China Hospital - Sichuan University
Chengdu, , China
No. 900 Hospital (Fuzhou General Hospital)
Fuzhou, , China
Fujian Cancer Hospital
Fuzhou, , China
Zhejiang Provincial People?s Hospital
Hangzhou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Shandong Cancer Hospital
Jinan, , China
The First Affiliated Hospital Of Jinzhou Medical University
Jinzhou, , China
Yunnan Cancer Hospital
Kunming, , China
Jiangxi Cancer Hospital
Nanchang, , China
Jiangsu Cancer Hospital
Nanjing, , China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, , China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, , China
The First Affiliated Hospital of China Medical University
Shenyang, , China
Tianjin Cancer Hospital
Tianjin, , China
The Tumor Hospital of Xinjiang Medical University
Ürümqi, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, , China
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Bogota, D.C., , Colombia
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia
Bogotá, , Colombia
Oncomedica S.A.
Montería, , Colombia
Oncólogos de Occidente
Pereira, , Colombia
Dar El salam Cancer Centre
Cairo, , Egypt
National Cancer Institute- Breast Cancer Treatment & Research Hospital - 5th settlement
Cairo, , Egypt
Sohag Oncology Center
Cairo, , Egypt
Institut Sainte Catherine
Avignon, , France
CH de la Côte Basque - Hôpital de Bayonne
Bayonne, , France
CHU Besançon - Hôpital Jean Minjoz
Besançon, , France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
CHU de GRENOBLE
Grenoble, , France
CHD Vendée
La Roche-sur-Yon, , France
Hopital Prive Jean Mermoz
Lyon, , France
INSTITUT CURIE_Site Paris
Paris, , France
Centre Catalan D' Oncologie
Perpignan, , France
Gesundheitszentrum Wetterau, Hochwaldkrankenhaus Bad Nauheim
Bad Nauheim, , Germany
Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie
Bamberg, , Germany
Gynäkologisches Zentrum Bonn
Bonn, , Germany
Onkozentrum Dres. Göhler
Dresden, , Germany
Kliniken Essen-Mitte
Essen, , Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, , Germany
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, , Germany
Ärztehaus am Bahnhofsplatz
Hildesheim, , Germany
Universitätsklinikum des Saarlandes
Homburg/Saar, , Germany
Dres. Andreas Köhler und Roswitha Fuchs
Langen, , Germany
MVZ für Hämatologie und Onkologie Ravensburg GmBH
Ravensburg, , Germany
Caritas-Krankenhaus St. Josef
Regensburg, , Germany
Klinikum Mutterhaus der Borromaeerinnen gGmbH
Trier, , Germany
Universitätsklinik Tübingen
Tübingen, , Germany
Budapesti Szent Margit Korhaz
Budapest, , Hungary
Semmelweis Egyetem;Onkológiai Profil (Belgyógyászati és Onkológiai Klinika)
Budapest, , Hungary
Bekes Varmegyei Központi Korhaz, Pandy Kalman Tagkorhaz
Gyula, , Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz
Kaposvár, , Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
Szolnok, , Hungary
Komarom-Eszergom Varmegyei Szent Borbala Korhaz
Tatabánya, , Hungary
Manipal Hospital
Bangalore, Karnataka, India
Tata Memorial Hospital
Mumbai, Maharashtra, India
Sahyadri Super Specialty Hospital Hadapsar
Pune, Maharashtra, India
Rajiv Gandhi Cancer Inst.&Research Center
New Delhi, National Capital Territory of Delhi, India
Fortis Hospital
New Delhi, National Capital Territory of Delhi, India
Netaji Subhas Chandra Bose Cancer Hospital
Kolkata, West Bengal, India
TATA Medical Centre
Kolkata, West Bengal, India
Azienda Ospedaliera Universitaria Federico II
Napoli, Campania, Italy
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE
Napoli, Campania, Italy
Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS
Reggio Emilia, Emilia-Romagna, Italy
Ospedale Infermi AUSL della Romagna
Rimini, Emilia-Romagna, Italy
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, Italy
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Humanitas Centro Catanese Di Oncologia
Misterbianco (CT), Sicily, Italy
Ospedale Civile
Livorno, Tuscany, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padua, Veneto, Italy
King Hussein Cancer Center
Amman, , Jordan
International Cancer Institute (ICI)
Eldoret, , Kenya
The Aga Khan University-Kenya.
Nairobi, , Kenya
Rizk Hospital
Beirut, , Lebanon
American University of Beirut - Medical Center
Beirut, , Lebanon
Investigacion Oncofarmaceutica
La Paz, Baja California Sur, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Iem-Fucam
D.F., Mexico CITY (federal District), Mexico
Health Pharma Professional Research
Mexico City, Mexico CITY (federal District), Mexico
Filios Alta Medicina
Monterrey, Nuevo León, Mexico
Hospital Universitario
Monterrey, Nuevo León, Mexico
Hospital Zambrano Hellion TecSalud
Monterrey, Nuevo León, Mexico
Cuidados oncologicos
Querétaro City, Querétaro, Mexico
Oncologico Potosino
San Luis Potosí City, San Luis Potosí, Mexico
Centro Estatal de Cancerologia de Chihuahua
Chihuahua City, , Mexico
Sultan Qaboos Comprehensive Cancer Care & Research Center
Muscat, , Oman
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gdansk, , Poland
Przychodnia Lekarska KOMED, Roman Karaszewski
Konin, , Poland
Szpital Wojewódzki im. Miko?aja Kopernika
Koszalin, , Poland
Opolskie Centrum Onkologii
Opole, , Poland
Ars Medical Sp. z o. o.
Pi?a, , Poland
Szpital Kliniczny im. H.Swiecickiego UM w Poznaniu
Późna, , Poland
MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie
Rzeszów, , Poland
Centrum Onkologii ? Instytut im. Marii Sk?odowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
Warsaw, , Poland
IPO de Coimbra
Coimbra, , Portugal
Hospital de S. Francisco Xavier
Lisbon, , Portugal
Hospital Beatriz Angelo
Loures, , Portugal
IPO do Porto
Porto, , Portugal
King Faisal Specialist Hospital & Research Centre
Riyadh, , Saudi Arabia
National Guard King Abdulaziz Medical City
Riyadh, , Saudi Arabia
King Fahad Medical City
Riyadh, , Saudi Arabia
Wits Donald Gordon Clinical Trial Centre
Parktown, Johannesburg, , South Africa
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
National Cancer Center
Goyang-si, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul St Mary's Hospital
Seoul, , South Korea
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Sant Andreu de la Barca, Barcelona, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, LA Coruna, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Hospital Clínic i Provincial
Barcelona, , Spain
Hospital Universitario Clínico San Cecilio
Granada, , Spain
Hospital Juan Ramon Jimenez
Huelva, , Spain
Centro Oncologico MD Anderson Internacional
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Clinico Universitario Virgen de la Victoria
Málaga, , Spain
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
Valencia, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Changhua Christian Hospital
Changhua, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital Office of General Surgery
Taipei, , Taiwan
Rajavithi Hospital
Bangkok, , Thailand
Ramathibodi Hospital
Bangkok, , Thailand
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, , Thailand
Songklanagarind Hospital
Songkhla, , Thailand
Adana Baskent University Hospital
Adana, , Turkey (Türkiye)
Ankara Oncology Hospital
Ankara, , Turkey (Türkiye)
Gazi Uni Medical Faculty Hospital
Ankara, , Turkey (Türkiye)
Ankara City Hospital
Ankara, , Turkey (Türkiye)
Dicle University Faculty of Medicine
Diyarbakır, , Turkey (Türkiye)
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
Edirne, , Turkey (Türkiye)
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department
Erzurum, , Turkey (Türkiye)
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, , Turkey (Türkiye)
Ac?badem Altunizade Hastanesi
Istanbul, , Turkey (Türkiye)
Ege Uni Medical Faculty
Izmir, , Turkey (Türkiye)
Katip Celebi University Ataturk Training and Research Hospital
Izmir, , Turkey (Türkiye)
Kocaeli University Faculty of Medicine
İzmit, , Turkey (Türkiye)
Erciyes Uni
Kayseri, , Turkey (Türkiye)
Antalya Memorial Hastanesi
Kepez, , Turkey (Türkiye)
Mersin City Education and Research Hospital
Mersin, , Turkey (Türkiye)
Ondokuz Mayis Univ. Med. Fac.
Samsun, , Turkey (Türkiye)
Medical Park Seyhan Hospital
Seyhan, , Turkey (Türkiye)
Namik Kemal Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, 100
Tekirdağ, , Turkey (Türkiye)
Uganda Cancer Institute
Kampala, , Uganda
Burjeel Medical City-Abu Dhabi
Abu Dhabi, , United Arab Emirates
Tawam Hospital
Al Ain City, , United Arab Emirates
Ysbyty Gwynedd Hospital
Bangor, , United Kingdom
Royal United Hospital
Bath, , United Kingdom
Blackpool Victoria Hospital
Blackpool, , United Kingdom
University Hospital North Tees
Cleveland, , United Kingdom
Charing Cross Hospital
London, , United Kingdom
Maidstone Hospital
Maidstone, , United Kingdom
Nottingham University Hospitals NHS Trust - City Hospital
Nottingham, , United Kingdom
Royal Preston Hosp
Preston, , United Kingdom
North Wales Cancer Treatment Centre, Glan Clwyd Hospital
Rhyl, , United Kingdom
Singleton Hospital
Swansea, , United Kingdom
Royal Cornwall Hospital
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Ozyilkan O, Morales-Vasquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer. 2024 May 24;24(1):641. doi: 10.1186/s12885-024-12179-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WO43571
Identifier Type: -
Identifier Source: org_study_id
2022-500014-26-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.